Bioline RX Ltd Sponsored ADR Stock

$2.75

2.63% yesterday

Nasdaq, Apr 16, 09:42 pm CET

ISIN

US09071M1062

Symbol

BLRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Bioline RX Ltd Sponsored ADR Stock price

$2.75

-66.45 96.03% 5Y

Nasdaq, Closing price Wed, Apr 16 2025

-0.07 2.63%

ISIN

US09071M1062

Symbol

BLRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$10.22m
Enterprise Value	$5.70m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.20
P/S ratio (TTM) P/S ratio	0.35
P/B ratio (TTM) P/B ratio	0.45
Revenue growth (TTM) Revenue growth	502.92%
Revenue (TTM) Revenue	$28.94m
EBIT (operating result TTM) EBIT	$-19.40m
Free Cash Flow (TTM) Free Cash Flow	$-43.93m
Cash position	$19.56m
EPS (TTM) EPS	$-4.48
P/E forward	negative
P/S forward	1.75
EV/Sales forward	0.98
Short interest	5.92%

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Get Started for Free Today

Bioline RX Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:

1x Buy

50%

1x Hold

50%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:

Buy

50%

Hold

50%

Analyst Estimates with Stock Price Targets

Financial data from Bioline RX Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	29 29	503% 503% 100%
- Direct Costs	10 10	130% 130% 35%
Gross Profit	19 19	4,298% 4,298% 65%
- Selling and Administrative Expenses	25 25	15% 15% 87%
- Research and Development Expense	9.15 9.15	27% 27% 32%
EBITDA	-15 -15	63% 63% -53%
- Depreciation and Amortization	4.09 4.09	196% 196% 14%
EBIT (Operating Income) EBIT	-19 -19	55% 55% -67%
Net Profit	-9.22 -9.22	85% 85% -32%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bioline RX Ltd Sponsored ADR Stock News

Neutral

Seeking Alpha

●

16 days ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

Neutral

PRNewsWire

●

17 days ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA ® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales - - Completed financings raising combined gro...

Neutral

PRNewsWire

●

24 days ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd.

More Bioline RX Ltd Sponsored ADR News

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Head office	Israel
CEO	Philip Serlin
Employees	28
Founded	2003
Website	www.biolinerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now